M Regina Castro1, Gyorgy Simon2, Stephen S Cha3, Barbara P Yawn4, L Joseph Melton5, Pedro J Caraballo6,7. 1. Department of Medicine, Division of Endocrinology, Mayo Clinic, Rochester, MN, USA. 2. Institute for Health Informatics, University of Minnesota, Minneapolis, MN, USA. 3. Department of Health Sciences Research, Division of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, USA. 4. Department of Research, Olmsted Medical Center, Rochester, MN, USA. 5. Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA. 6. Department of Medicine, Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA. caraballo.pedro@mayo.edu. 7. Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. caraballo.pedro@mayo.edu.
Abstract
BACKGROUND: The association between the use of statins and the risk of diabetes and increased mortality within the same population has been a source of controversy, and may underestimate the value of statins for patients at risk. OBJECTIVE: We aimed to assess whether statin use increases the risk of developing diabetes or affects overall mortality among normoglycemic patients and patients with impaired fasting glucose (IFG). DESIGN AND PARTICIPANTS: Observational cohort study of 13,508 normoglycemic patients (n = 4460; 33% taking statins) and 4563 IFG patients (n = 1865; 41% taking statin) among residents of Olmsted County, Minnesota, with clinical data in the Mayo Clinic electronic medical record and at least one outpatient fasting glucose test between 1999 and 2004. Demographics, vital signs, tobacco use, laboratory results, medications and comorbidities were obtained by electronic search for the period 1999-2004. Results were analyzed by Cox proportional hazards models, and the risk of incident diabetes and mortality were analyzed by survival curves using the Kaplan-Meier method. MAIN MEASURES: The main endpoints were new clinical diagnosis of diabetes mellitus and total mortality. KEY RESULTS: After a mean of 6 years of follow-up, statin use was found to be associated with an increased risk of incident diabetes in the normoglycemic (HR 1.19; 95% CI, 1.05 to 1.35; p = 0.007) and IFG groups (HR 1.24; 95%CI, 1.11 to 1.38; p = 0.0001). At the same time, overall mortality decreased in both normoglycemic (HR 0.70; 95% CI, 0.66 to 0.80; p < 0.0001) and IFG patients (HR 0.77, 95% CI, 0.64 to 0.91; p = 0.0029) with statin use. CONCLUSION: In general, recommendations for statin use should not be affected by concerns over an increased risk of developing diabetes, since the benefit of reduced mortality clearly outweighs this small (19-24%) risk.
BACKGROUND: The association between the use of statins and the risk of diabetes and increased mortality within the same population has been a source of controversy, and may underestimate the value of statins for patients at risk. OBJECTIVE: We aimed to assess whether statin use increases the risk of developing diabetes or affects overall mortality among normoglycemic patients and patients with impaired fasting glucose (IFG). DESIGN AND PARTICIPANTS: Observational cohort study of 13,508 normoglycemic patients (n = 4460; 33% taking statins) and 4563 IFG patients (n = 1865; 41% taking statin) among residents of Olmsted County, Minnesota, with clinical data in the Mayo Clinic electronic medical record and at least one outpatient fasting glucose test between 1999 and 2004. Demographics, vital signs, tobacco use, laboratory results, medications and comorbidities were obtained by electronic search for the period 1999-2004. Results were analyzed by Cox proportional hazards models, and the risk of incident diabetes and mortality were analyzed by survival curves using the Kaplan-Meier method. MAIN MEASURES: The main endpoints were new clinical diagnosis of diabetes mellitus and total mortality. KEY RESULTS: After a mean of 6 years of follow-up, statin use was found to be associated with an increased risk of incident diabetes in the normoglycemic (HR 1.19; 95% CI, 1.05 to 1.35; p = 0.007) and IFG groups (HR 1.24; 95%CI, 1.11 to 1.38; p = 0.0001). At the same time, overall mortality decreased in both normoglycemic (HR 0.70; 95% CI, 0.66 to 0.80; p < 0.0001) and IFG patients (HR 0.77, 95% CI, 0.64 to 0.91; p = 0.0029) with statin use. CONCLUSION: In general, recommendations for statin use should not be affected by concerns over an increased risk of developing diabetes, since the benefit of reduced mortality clearly outweighs this small (19-24%) risk.
Authors: Annie L Culver; Ira S Ockene; Raji Balasubramanian; Barbara C Olendzki; Deidre M Sepavich; Jean Wactawski-Wende; Joann E Manson; Yongxia Qiao; Simin Liu; Philip A Merriam; Catherine Rahilly-Tierny; Fridtjof Thomas; Jeffrey S Berger; Judith K Ockene; J David Curb; Yunsheng Ma Journal: Arch Intern Med Date: 2012-01-09
Authors: David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray Journal: JAMA Date: 2011-06-22 Impact factor: 56.272
Authors: Anthony Keech; David Colquhoun; James Best; Adrienne Kirby; R John Simes; David Hunt; Wendy Hague; Elaine Beller; Manjula Arulchelvam; Jennifer Baker; Andrew Tonkin Journal: Diabetes Care Date: 2003-10 Impact factor: 19.112
Authors: N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh Journal: Lancet Date: 2010-06-26 Impact factor: 202.731
Authors: Jaana Lindström; Anne Louheranta; Marjo Mannelin; Merja Rastas; Virpi Salminen; Johan Eriksson; Matti Uusitupa; Jaakko Tuomilehto Journal: Diabetes Care Date: 2003-12 Impact factor: 19.112
Authors: J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto Journal: JAMA Date: 1998-05-27 Impact factor: 56.272
Authors: Edward J Mills; Beth Rachlis; Ping Wu; Philip J Devereaux; Paul Arora; Dan Perri Journal: J Am Coll Cardiol Date: 2008-11-25 Impact factor: 24.094
Authors: Srikanth Tangelloju; Bert B Little; Robert J Esterhay; Guy Brock; Scott LaJoie Journal: Diabetes Metab Res Rev Date: 2020-04-03 Impact factor: 8.128
Authors: Mark Moeller; Christiane Pink; Nicole Endlich; Karlhans Endlich; Hans-Jörgen Grabe; Henry Völzke; Marcus Dörr; Matthias Nauck; Markus M Lerch; Rüdiger Köhling; Birte Holtfreter; Thomas Kocher; Georg Fuellen Journal: PLoS One Date: 2017-04-19 Impact factor: 3.240